221 related articles for article (PubMed ID: 33762178)
1. Validity of different dose reduction criteria for apixaban.
Hawkins NM; Er L; Sandhu RK; Kaul P; McAlister FA; Levin A; Andrade JG
Am Heart J; 2021 Aug; 238():12-15. PubMed ID: 33762178
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes according to dose reduction criteria of apixaban in Japanese elderly patients with atrial fibrillation: J-ELD AF Registry subanalysis.
Akao M; Yamashita T; Suzuki S; Okumura K;
Heart Vessels; 2021 Jul; 36(7):1035-1046. PubMed ID: 33486555
[TBL] [Abstract][Full Text] [Related]
3. Initial apixaban dosing in patients with atrial fibrillation.
Buchholz A; Ueberham L; Gorczynska K; Dinov B; Hilbert S; Dagres N; Husser D; Hindricks G; Bollmann A
Clin Cardiol; 2018 May; 41(5):671-676. PubMed ID: 29542830
[TBL] [Abstract][Full Text] [Related]
4. Apixaban is dear to me, but dearer still is warfarin.
Di Biase L; Natale A
Pacing Clin Electrophysiol; 2015 Feb; 38(2):153-4. PubMed ID: 25625880
[No Abstract] [Full Text] [Related]
5. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy.
Barra ME; Fanikos J; Connors JM; Sylvester KW; Piazza G; Goldhaber SZ
Am J Med; 2016 Nov; 129(11):1198-1204. PubMed ID: 27341955
[TBL] [Abstract][Full Text] [Related]
6. Prescribing of Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of Renal Function Using Standard and Modified Cockcroft-Gault Equations: A Retrospective Analysis.
Kucey M; Bolt J; Albers L; Bell A; Iroh N; Toppings J
Can J Hosp Pharm; 2016; 69(5):409-414. PubMed ID: 27826159
[No Abstract] [Full Text] [Related]
7. Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure.
Andreu-Cayuelas JM; Pastor-Pérez FJ; Puche CM; Mateo-Martínez A; García-Alberola A; Flores-Blanco PJ; Valdés M; Lip GY; Roldán V; Manzano-Fernández S
Rev Esp Cardiol (Engl Ed); 2016 Feb; 69(2):134-40. PubMed ID: 26607030
[TBL] [Abstract][Full Text] [Related]
8. Predictors for a high apixaban level in elderly patients with atrial fibrillation prescribed reduced dose of apixaban.
Suzuki S; Yamashita T; Akao M; Okumura K
Eur J Clin Pharmacol; 2021 Nov; 77(11):1757-1758. PubMed ID: 34014337
[No Abstract] [Full Text] [Related]
9. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial.
Alexander JH; Andersson U; Lopes RD; Hijazi Z; Hohnloser SH; Ezekowitz JA; Halvorsen S; Hanna M; Commerford P; Ruzyllo W; Huber K; Al-Khatib SM; Granger CB; Wallentin L;
JAMA Cardiol; 2016 Sep; 1(6):673-81. PubMed ID: 27463942
[TBL] [Abstract][Full Text] [Related]
10. Effect of pre-procedural interrupted apixaban on heparin anticoagulation during catheter ablation for atrial fibrillation: a prospective observational study.
Bin Abdulhak AA; Kennedy KF; Gupta S; Giocondo M; Ramza B; Wimmer AP
J Interv Card Electrophysiol; 2015 Nov; 44(2):91-6. PubMed ID: 26292959
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587
[TBL] [Abstract][Full Text] [Related]
12. Safety outcomes of apixaban in patients with nonvalvular atrial fibrillation and severe renal impairment.
Jones MJ; Eudaley ST; Moye RA; Hodge TA; Nesbit RM; Franks AS
J Thromb Thrombolysis; 2020 Aug; 50(2):330-336. PubMed ID: 31902123
[TBL] [Abstract][Full Text] [Related]
13. Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment.
Hawkins NM; Jhund PS; Pozzi A; O'Meara E; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Petrie MC; Virani S; McMurray JJ
Eur J Heart Fail; 2016 Sep; 18(9):1162-71. PubMed ID: 27594177
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
Held C; Hylek EM; Alexander JH; Hanna M; Lopes RD; Wojdyla DM; Thomas L; Al-Khalidi H; Alings M; Xavier D; Ansell J; Goto S; Ruzyllo W; Rosenqvist M; Verheugt FW; Zhu J; Granger CB; Wallentin L
Eur Heart J; 2015 May; 36(20):1264-72. PubMed ID: 25499871
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial.
Zeitouni M; Giczewska A; Lopes RD; Wojdyla DM; Christersson C; Siegbahn A; De Caterina R; Steg PG; Granger CB; Wallentin L; Alexander JH;
J Am Coll Cardiol; 2020 Mar; 75(10):1145-1155. PubMed ID: 32164888
[TBL] [Abstract][Full Text] [Related]
16. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
17. Apixaban: a new direct oral anticoagulant for stroke prevention in atrial fibrillation.
Hohnloser SH
Eur Heart J; 2014 Jul; 35(28):1828-9. PubMed ID: 25184177
[TBL] [Abstract][Full Text] [Related]
18. [Oral anticoagulation in patients with atrial fibrillation and stage 4 or 5 chronic kidney disease].
Petricciuolo S; Aimo A; De Caterina R
G Ital Cardiol (Rome); 2020 Jan; 21(1):6-15. PubMed ID: 31960830
[TBL] [Abstract][Full Text] [Related]
19. Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial.
Berglund E; Wallentin L; Oldgren J; Renlund H; Alexander JH; Granger CB; Hohnloser SH; Hylek EM; Lopes RD; McMurray JJ; Lytsy P
Eur J Prev Cardiol; 2020 Aug; 27(12):1311-1319. PubMed ID: 31698965
[TBL] [Abstract][Full Text] [Related]
20. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease.
Altawalbeh SM; Alshogran OY; Smith KJ
Value Health; 2018 Dec; 21(12):1365-1372. PubMed ID: 30502779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
